Critical assessment of the current guidelines for the management and treatment of morbidly obese patients (original) (raw)
Flegal KM CM, Carroll MD, Ogden DL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288: 1723–7. ArticlePubMed Google Scholar
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999, 341: 1097–105. ArticleCASPubMed Google Scholar
Field A, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161: 1581–6. ArticleCASPubMed Google Scholar
Wang Y. Cross-national comparison of childhood obesity: the epidemic and the relationship between obesity and socioeconomic status. Int J Epidemiol 2001, 30: 1129–36. ArticleCASPubMed Google Scholar
Buchwald H; Consensus Conference Panel. Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. J Am Coll Surg 2005, 200: 593–604. ArticlePubMed Google Scholar
Lobstein T, Frelut ML. Prevalence of overweight among children in Europe. Obes Rev 2003, 4: 195–200. ArticleCASPubMed Google Scholar
Department of Health 2001. Health Survey for England. www.doh.gov.uk/.
Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban B; Grupo Colaborativo SEEDO. Prevalence of obesity in Spain. Med Clin (Barc) 2005, 125: 460–6. Article Google Scholar
Kaminsky J, Gadaleta D. A study of discrimination within the medical community as viewed by obese patients. Obes Surg 2002, 12: 14–8. ArticlePubMed Google Scholar
Cawley J, Danziger S. Morbid obesity and the transition from welfare to work. J Policy Anal Manage 2005, 24: 727–43. ArticlePubMed Google Scholar
NIH Conference: Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991, 115: 956–61. Google Scholar
Guidance on the use of surgery to aid weight reduction for people with morbid obesity. NICE Technology Appraisal Guidance — No. 46. 2002.
Sjostrom L, Lindroos AK, Peltonen M, et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351: 2683–93. ArticlePubMed Google Scholar
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999, 282: 1523–9. ArticleCASPubMed Google Scholar
Cook CM, Edwards C. Success habits of long-term gastric bypass patients. Obes Surg 1999, 9: 80–2. ArticleCASPubMed Google Scholar
Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg 2004, 14: 1148–56. ArticlePubMed Google Scholar
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346: 1623–30. ArticlePubMed Google Scholar
Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003, 11: 919–24. ArticleCASPubMed Google Scholar
Frühbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004, 350: 308–9. ArticlePubMed Google Scholar
Couce ME, Cottam DR, Esplen J, Schauer P, Burguera B. Is ghrelin the culprit of weight loss after gastric bypass surgery? A negative answer. Obes Surg 2006, 16: 870–8. ArticlePubMed Google Scholar
Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88: 1594–602. ArticleCASPubMed Google Scholar
Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003, 88: 3177–83. ArticleCASPubMed Google Scholar
Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004, 12: 346–50. ArticleCASPubMed Google Scholar
Morínigo R, Moizé V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006, 91: 1735–40. ArticlePubMed Google Scholar
Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006, 243: 108–14. ArticlePubMed CentralPubMed Google Scholar
Wing RR, Blair EH, Marcus MD, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994, 97: 354–62. Google Scholar
Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004, 164: 994–1003. ArticleCASPubMed Google Scholar
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27: 155–61. ArticleCASPubMed Google Scholar
Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001, 25: 1713–21. ArticleCASPubMed Google Scholar
Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58: 582–7. ArticleCASPubMed Google Scholar
Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisnieewski, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001, 161: 218–27. ArticleCASPubMed Google Scholar
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353: 2111–20. ArticleCASPubMed Google Scholar
Frühbeck G, Rotellar F, Hernández-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg 2004, 14: 1208–15. ArticlePubMed Google Scholar
Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999, 7: 477–84. ArticleCASPubMed Google Scholar
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222: 339–50. ArticleCASPubMed CentralPubMed Google Scholar
Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Bilio-pancreatic bypass for obesity. II. Initial experience in man. Br J Surg 1979, 66: 619–20. Google Scholar
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003, 238: 467–84. PubMed CentralPubMed Google Scholar
Scopinaro N, Marinari GM, Camerini GB, Papadia FS, Adami GF. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005, 28: 2406–11. ArticlePubMed Google Scholar
Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A. 2001, 11: 377–82. ArticleCASPubMed Google Scholar